CFT7455
Modify Date: 2025-08-27 11:20:16
CFT7455 structure
|
Common Name | CFT7455 | ||
|---|---|---|---|---|
| CAS Number | 2504233-68-3 | Molecular Weight | 469.541 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C28H27N3O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CFT7455CFT7455 is a highly potent and selective degarder of IKZF1/3 with cereblon binding IC50 of 0.4 nM and picomolar DC50.Treatment of the KiJK cell line of anaplastic large cell lymphoma (ALCL) with CFT7455 for 6 hours led to an 89% reduction in IKZF1 protein levels.CFT7455 demonstrated potent antiproliferative activity across a panel of NHL cell lines with MYC, BCL2, and/or BCL6 translocations or rearrangements.CFT7455 is an orally bioavailable.CFT7455 achieved improved in vivo potency and efficacy, including deeper and more durable tumor regressions in models of ALCL, diffuse large B-cell lymphoma (DLBCL) and MCL in xenograft models. |
| Name | CFT7455 |
|---|
| Description | CFT7455 is a highly potent and selective degarder of IKZF1/3 with cereblon binding IC50 of 0.4 nM and picomolar DC50.Treatment of the KiJK cell line of anaplastic large cell lymphoma (ALCL) with CFT7455 for 6 hours led to an 89% reduction in IKZF1 protein levels.CFT7455 demonstrated potent antiproliferative activity across a panel of NHL cell lines with MYC, BCL2, and/or BCL6 translocations or rearrangements.CFT7455 is an orally bioavailable.CFT7455 achieved improved in vivo potency and efficacy, including deeper and more durable tumor regressions in models of ALCL, diffuse large B-cell lymphoma (DLBCL) and MCL in xenograft models. |
|---|
| Molecular Formula | C28H27N3O4 |
|---|---|
| Molecular Weight | 469.541 |
| InChIKey | MUKCJOOKCZSQNW-UHFFFAOYSA-N |
| SMILES | O=C1CCC(N2C(=O)c3cccc4c(Cc5ccc(CN6CCOCC6)cc5)ccc2c34)C(=O)N1 |